=====================Kali,Alert Price: $0.Float: 6.74M (OTC Markets)Website | Recent News========================Thesector just got a huge endorsement from one of pro sport's biggest personalities.Former Super Bowl-winning tight end, Rob Gronkowski, is the latest ex-athlete to step into the cannabis industry.During a press conference held in New York City on Monday, Gronk announced that he's partnering with Abacus Health Products and its line of topicalproducts called CBDMEDIC. Little is known about his deal with Abacus Health Products, but according toNetwork'sRapoport, Gronkowski's goal is to advocate for the legalization ofproducts by professional sports leagues."I’m here to appeal to the sports governing bodies to update their positions onused by all players," Gronk told the audience. "For the first time in a decade, I’m pain-free."Today's news should give the entiresector a nice lift, and one company that could benefit isThe last time we broughtto your attention shares ran up from $0.009 to a high of $0.185 for a single session gain of +105%.is now trading back at a highly attractive price of $0.per share, and we're betting on another run-up this week.Here's why...KALY- Kali-Extracts Announces New Analyst Report Speculating $0.05Following Recent Biopharmaceutical Cannabis Extract UpdatesMoments ago,announced a new analyst report covering the company’s recent biopharmaceutical cannabis extract business development updates. The report has been released by Goldman Small Cap Research after market today, August 27, 2019, and can be found on Goldman’s website http://www.goldmanresearch.com. The report speculates a potentialprice per share of $0.05.“Already generating major revenue growth and operating profit, a series of near-term revenue and pharmaceutical development milestones bywarrant a closer look by investors as these shares could trade to the $0.05 level in the near term.”The analyst report update initiative was triggered by KALY’s recentupdate on the company’s cannabis extract biopharmaceutical business pursuing $170 billion in pharmaceutical treatments where theannounced new patent and trademark applications on KALY’sFormulation for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The report includes coverage on theof the company’s recently announcedextraction contracts with hemp farming operations worth $15 million, and coverage of the company’s recently posted 2019 YTD financials reporting 250% revenue growth. The analyst report also addresses KALY’s ongoing business partnership with) and the sales of KALY’s Hemp4mulacandy line through NorthHoldings, Inc’s () ecommerce site www..com.“When we last left Kali,(OTC –) dba/Kali-Extracts,in January 2019, the Company was full of promise and in our view, well-positioned to emerge as a future leader in its key segments of thearena. Seven months later,has dramatically exceeded our expectations with respect to revenue and new business, along with product development and its overall industry positioning. The successes on the product development and commercialization fronts appear to serve as potential catalysts to favourablyKALY’s stock and valuation, thus affirming the value of its current and future.”To view the full report visit https://www.goldmanresearch.com/ To learn more about the company visit https://www.kali-extracts.com/ Sees 250% Revenue Growth From New Cannabis Business With Even More Dramatic Growth Anticipated In Second Half Of 20191st Six Months 2019 Revenue Is $165,000 Compared To $46,000 Last YearAlso Reported $70,000 Operating Net Income 1st Six Months 2019• 250% Revenue Growth Results From Q4 2018 Cannabis Business Acquired Q4 2018Owns And Operates Patented Cannabis Extraction Process And Has Filed For A Second Patent On A New BiopharmaceuticalFormulation• Hemp FarmingExtraction Contracts Anticipated To Result In Even More Dramatic Revenue Growth In Second Half Of 2019Plans To Publish Website Tomorrow Dedicated To NewFormulation And Corresponding Patent ApplicationAnticipates An Analyst Update To Be Published On The Company Next WeekLast week,announced the publishing of its up-to-date corporate financials through the end of Q2 2019.realized $165,000 in revenue in the first six months of 2019. The revenue results from the company’s cannabis business shift in the fourth quarter of last year. In the first six months of 2018,reported only $46,000 in sales. The introduction of KALY’s new cannabis business has seen the company’s revenue grow over 250% in the first six months of 2019 compared to the first six months of 2018.also realized $70,000 in operating net income in the first six months of 2019.reported only nominal operating net income in the first six months of 2018.In the fourth quarter of last year, 2018,acquiredBiotech (NCMB). NCMB owns and operates a U.S. Patent for cannabis extraction. With the acquisition of NCMB,is now primarily in the business of developing biopharmaceutical formulations from cannabis extractions for the treatment of various diseases.now has over four years of research and development behind cannabis extract formulations targeting the treatment of Chronic Obstructive Pulmonary Disease (COPD), Cancer Pain Management, Type 2 Diabetes and Epilepsy.Earlier this week,announced filing a new patent application specifically on its formulation for symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s existing patented cannabis extraction process. The company has also filed to register a trademark on the name RESPRX as the brand name for itsformulation to treat the symptoms associated with COPD and other similar respiratory conditions.plans to publish a website on Friday, August 23rd, dedicated to its newformulation, RESPRX, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The RESPRX website to be published Friday will include details on KALY’s recent patent and trademark applications for the RESPRXformulation.has implemented a long-term sustainable overall business strategy.is not just relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market., through partnership and independently, has also introduced to market a number ofinfused consumer food products. The revenue realized in the first six months of 2019 comes primarily from KALY’s variousinfusion offerings.Drawing on KALY’s patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations.management anticipates even more dramatic revenue growth in the second half of 2019 as hemp harvest season approaches.management is committed to providing timely disclosures consistent with OTC Markets’ Pink Current Information Alternative Reporting Standard. Shortly after executing the acquisition of NCMB and implementing a cannabis business shift, OTC Markets implemented a buyer beware flag urging caution in regard to ainvestment.management continues to work toward resolving the concerns that resulted in the flag. In the meantime,management has published an alternative disclosure site in order to provide timely disclosures of the most up-to-date corporate information. The up-to-date corporate financial information referenced in this release can be found on the company’s alternative disclosure site – http://www.kaly-info.com. At just one-cent per share,Leads in‘Boom’ Market and Stands Ready For Follow on US Marijuana LegalizationThe rise of the marijuana industry over the past several years has been monumental, and 2018 in particular was ground breaking for cannabis-related businesses. After watching for years as individual U.S. states legalized marijuana one by one for various purposes, the entire nation of Canada took a great leap forward by making recreational cannabis legal across the country in mid-October. Gradually, more jurisdictions across the globe have decided to eliminate laws against marijuana, and the movement seems to be gaining even more momentum in 2019.The Cannabis ETF ), the first passively managed pure-play ETF solution for investing in cannabis, is now available to investors. The Cannabis ETF comes from Innovation Shares, a sponsor of unique thematic exchange traded funds. At the same time the cannabis pure play ETF was launched, the US House of Representatives began discussing the Federal Legalization of Marijuana.management views KALY’s strategy as an optimal fit into the cannabis investment opportunity reflected by thelaunch and Federal Legalization of Marijuana discussion.The Bullish Case For KALY:• KALY’s patented extraction process offers arguably the highest quality extract to the infusion market.• The company is currently developing Cannabis Extract Biopharmaceutical Therapies targeting $170 billion in market potential.• KALY’s non-pharmaceutical extraction revenue strategy offers a business line that can stand alone, and at the same time providewith the long-term staying power to bring its cannabis extract biopharmaceutical products to market.• Kali-Extracts MobileExtraction Is A Service In High Demand And Could Blow By $20 Million Revenue Target• Has announced $15 million in hemp derivedextraction contracts.• Management anticipates a dramatic revenue increase in the second half of 2019 in conjunction with the hemp extraction contracts announced earlier this summer.• Plans to AddInfused, Tea, and Beer to List of New DevelopmentsConfirms Cannabis Biopharmaceutical Update Targeting $170 Billion MarketKali-Extracts Announces RESPRXFormulation For Symptoms Associated With COPD – A $14 Billion Market OpportunityDevelops COPD TreatmentFormulation from Its Patented Extraction ProcessFiles New Patent Application on ItsFormulation for the Treatment of COPDFiles Trademark Registration on RESPRX Brand Name for COPD Treatment• Market for COPD Treatment Anticipated to Reach $14 Billionto File Up-To-Date Corporate Financials on Thursday This Weekto Publish RESPRX Website with Patent and Trademark Details on FridayLast weekreleased an update fromFrederick Ferri on the company’s ongoing Cannabis Extract Biopharmaceutical developments.owns and operates a U.S. Patent for cannabis extraction. The update today highlights the company’sformulation for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s patented cannabis extraction process. In conjunction with the research already conducted and the next phase of research now moving forward,today announces the filing of a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions.also announces the filing of a trademark on the name RESPRX as the brand name for itsformulation to treat the symptoms associated with COPD and other similar respiratory conditions. The market for COPD treatment is anticipated to reach $14 billion by 2025. In addition to the further updates included in the narrative herein to follow,plans to release additional corporate information later this week on Thursday, August 22nd. On Friday, August 23rd,plans to publish a website specifically dedicated to detailed information on RESPRX.Fredrick Ferri’s Comprehensive Update:Over four years ago, I founded NatureMeds to develop various therapies from cannabis extracts to treat specific health issues. The company transformed into what was later calledBiotech (NCMB). In the fourth quarter of last year, 2018,acquired NCMB. In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drugand patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.now has a deep pipeline of cannabinoid product candidates including four distinct compounds listed here:Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026;Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, andEpilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022.In addition to the research already published on the company’sformulation for the treatment of symptoms associated with COPD and other respiratory conditions,has initiated a next stage of clinical development and testing for its COPD therapy.is also currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.As already mentioned above, theformulation for the treatment of symptoms associated with COPD and other respiratory conditions is clearly unique and the testing to date has demonstrated sufficient efficacy to warrant our patent protection. Accordingly, on behalf of the company, I have filed for a patent on theformulation for the treatment of symptoms associated with COPD and other respiratory conditions. I have also filed for a trademark registration on the name RESPRX to delineate a brand name for theformulation for the treatment of symptoms associated with COPD and other respiratory conditions.has announced $15 million in hemp derivedextraction contracts.is leveraging its US Patented cannabis extraction process to establish a leadership position in the boomingmarket. At the same timeis prepared to leverage its US Patented cannabis extraction process within the inevitably legalized US recreational marijuana market.A CNBC article reporting on the US House of Representatives discussion on the Legalization of Marijuana Federally, commented that, “Eleven states have legalized adult recreational use and a majority of Americans support legalization.”Pharmaceutical Business andandPartnershipsis primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In the fourth quarter of last year, 2018,acquiredBiotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drugand patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.has a deep pipeline of cannabinoid product candidates including four distinct compounds.has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success. With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market. Drawing on KALY’s patented cannabis extraction expertise, in addition to winning the $5 million extraction contract mentioned above,has partnered with) to lend its extraction expertise in the production of EVERxSports Water, the leadinginfused beverage for the sports nutrition market.has also introduced its ownconfections line, Hemp4mula withinfused gum already on the market and gummies on the way. Hemp4mula is available on the Ecommerce site.com hosted by NorthHoldings,) (). KALY’s non-pharmaceutical extraction revenue strategy offers a business line that can stand alone, and at the same time providewith the long-term staying power to bring its cannabis extract biopharmaceutical products to market.Kali-Extracts MobileExtraction Is A Service In High Demand And Could Blow By $20 Million Revenue TargetIn late July,management confirmed a growing market interest in the company’s mobileextraction service.owns and operates a U.S. Patented Cannabis Extraction Process. The company recently announced building its Patented extraction process into a mobile unit to provide onsite hemp extraction. The company has announced $15 million worth ofextraction contracts so far and a target $20 million in 2019 revenue. With harvest season fast approaching, KALY’s mobile extraction unit will soon hit the road and the potential orders for KALY’sextraction service are stacking up. The company anticipates announcing new contracts soon.recently published a management overview on the company’s mobile cannabis extraction capacity. See the full presentation: https://www.kali-extracts.com/extraction... Kali-Extracts Mobile Cannabis Extraction CapacityKALY’s patented extraction process offers arguably the highest quality extract to the infusion market.With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably the highest quality extract to the infusion market., through partnership and independently, has also introduced to market a number ofinfused consumer food products. Drawing on KALY’s patented cannabis extraction expertise, the company has recently announced $15 million worth of extraction contracts with hemp farming operations.anticipates a dramatic revenue increase in the second half of 2019management anticipates a dramatic revenue increase in the second half of 2019 in conjunction with the hemp extraction contracts announced earlier this summer. So far,has announced two contracts to extractfrom hemp worth a total combined potential of $15 million. Management has set a target to sign $20 million inextraction contracts this year. Additionalextraction contracts are in the works. The company plans to self-disclose current financials through the second quarter of 2019 next week. Current revenues are derived from the sale of the company’s owninfused candies and the company’s licensing of its patented cannabis extraction process. The addition of revenue from the extraction offrom upcoming hemp harvests is anticipated to dramatically increase revenue in the second half of 2019.AddsInfused, Tea, and Beer to List of New DevelopmentsTwo weeks ago,andconfirmed addinginfused tea to its new line ofbeverage partnerships. Last week,andpublished a management presentation to provide shareholders with more details on PURA’s recently implemented program to introduceinfused versions of existing third-party beverages.has recently announced plans to introduce ainfused beer in partnership with an existing beer producer. In similar fashion,is partnering with an existingproducer to introduce ainfused. In conjunction with the presentation published last week,announced a third partnership to developinfused tea. Additional partnerships are in the works.is a leadinginfused beverage company having produced over $1 million inBeverages in the United States last year.has targeted $4 million in sales for 2019. The presentation is included in its entirety on the company’s website.About Kali,is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In the fourth quarter of last year, 2018,acquiredBiotech (NCMB). In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drugand patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.has a deep pipeline of cannabinoid product candidates including four distinct compounds.has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.DISCLAIMERThis newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negativeon share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by Awareness Consulting Network to conduct an up to one week investor relations advertising and marketing campaign forwhich includes up to 5,000 investor views. We have previously been compensated ten thousand dollars by Awareness Consulting Network to conduct an up to one week investor relations advertising and marketing campaign forwhich included up to 5,000 investor views -which has expired. Any compensation is a major conflict of interest in ourto be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.